Seven-year Safety and Efficacy of Somapacitan in Children With GH Deficiency: Final Results From REAL 3
After 7 years of treatment, children with GHD receiving somapacitan experienced consistent increases in height SDS and reduced treatment burden. No new safety concerns were identified.
Authors
- Reiko Horikawa (ORCID: https://orcid.org/0000-0003-3429-3246)
- Tina Lund Leunbach (ORCID: https://orcid.org/0000-0001-7996-7596)
- Lawrence A. Silverman
- Paul Saenger
- Lars Sävendahl (ORCID: https://orcid.org/0000-0003-1067-4976)
- Tadej Battelino (ORCID: https://orcid.org/0000-0002-0273-4732)
- Michael Højby
Institutions
- Karolinska University Hospital (SE)
- University of Ljubljana (SI)
- Novo Nordisk (Denmark) (DK)
- Ljubljana University Medical Centre (SI)
- NYU Langone Health (US)
- Goryeb Children's Hospital (US)
- National Center For Child Health and Development (JP)
Publication Details
- Journal
- Journal of the Endocrine Society
- Published
- 2025-11-19
- DOI
- https://doi.org/10.1210/jendso/bvaf189
- Citations
- 2
- Primary Topic
- Growth Hormone and Insulin-like Growth Factors
- Type
- article
- Field-Weighted Citation Impact
- 2.59